Literature DB >> 10775225

Ulcerative colitis.

S Ghosh1, A Shand, A Ferguson.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 10775225      PMCID： PMC1127254          DOI： 10.1136/bmj.320.7242.1119

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  47 in total

1.  Balsalazide led to greater remission rates and tolerance than mesalamine in acute ulcerative colitis.

Authors:  S B Hanauer
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

2.  Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis.

Authors:  W A Stack; R G Long; C J Hawkey
Journal:  Aliment Pharmacol Ther       Date:  1998-10       Impact factor: 8.171

3.  A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial.

Authors:  P Gionchetti; S Ardizzone; M E Benvenuti; G Bianchi Porro; G Biasco; P Cesari; G D'albasio; R De Franchis; G Monteleone; F Pallone; T Ranzi; G Trallori; D Valpiani; M Vecchi; M Campieri
Journal:  Aliment Pharmacol Ther       Date:  1999-03       Impact factor: 8.171

4.  Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis.

Authors:  J K Marshall; E J Irvine
Journal:  Gut       Date:  1997-06       Impact factor: 23.059

5.  Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation.

Authors:  E V Loftus; H I Aguilar; W J Sandborn; W J Tremaine; R A Krom; A R Zinsmeister; I W Graziadei; R H Wiesner
Journal:  Hepatology       Date:  1998-03       Impact factor: 17.425

6.  A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin.

Authors:  R D Cohen; A L Brodsky; S B Hanauer
Journal:  Inflamm Bowel Dis       Date:  1999-02       Impact factor: 5.325

7.  Evaluation of the usefulness of testing for p53 mutations in colorectal cancer surveillance for ulcerative colitis.

Authors:  B A Lashner; B D Shapiro; A Husain; J R Goldblum
Journal:  Am J Gastroenterol       Date:  1999-02       Impact factor: 10.864

8.  Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: defined specificities may be associated with distinct clinical features.

Authors:  C Roozendaal; A W Van Milligen de Wit; E B Haagsma; G Horst; C Schwarze; H H Peter; J H Kleibeuker; J W Tervaert; P C Limburg; C G Kallenberg
Journal:  Am J Med       Date:  1998-11       Impact factor: 4.965

9.  Treatment of corticosteroid-resistant ulcerative colitis with heparin--a report of 16 cases.

Authors:  R C Evans; V S Wong; A I Morris; J M Rhodes
Journal:  Aliment Pharmacol Ther       Date:  1997-12       Impact factor: 8.171

10.  Ileoanal pouch procedures: clinical outcomes and quality-of-life assessment.

Authors:  S A Seidel; S E Peach; M Newman; K W Sharp
Journal:  Am Surg       Date:  1999-01       Impact factor: 0.688
View more
  11 in total

1.  Ulcerative colitis should be investigated differently in children.

Authors:  R K Russell; P M Gillett; D C Wilson
Journal:  BMJ       Date:  2000-09-02

2.  Factors affecting health related quality of life of patients with inflammatory bowel disease.

Authors:  Francesc Casellas; Josefa López-Vivancos; Alfonso Casado; Juan-Ramon Malagelada
Journal:  Qual Life Res       Date:  2002-12       Impact factor: 4.147

3.  An 18-month study of the effects of IBD symptomatology and emotion regulation on depressed mood.

Authors:  Inês A Trindade; Cláudia Ferreira; Mariana Moura-Ramos; José Pinto-Gouveia
Journal:  Int J Colorectal Dis       Date:  2017-02-09       Impact factor: 2.571

4.  Ulcerative Colitis Symptomatology and Depression: The Exacerbator Role of Maladaptive Psychological Processes.

Authors:  Inês A Trindade; Cláudia Ferreira; José Pinto-Gouveia
Journal:  Dig Dis Sci       Date:  2015-07-04       Impact factor: 3.199

5.  The impact of ulcerative colitis on patients' lives compared to other chronic diseases: a patient survey.

Authors:  David T Rubin; Marla C Dubinsky; Remo Panaccione; Corey A Siegel; David G Binion; Sunanda V Kane; Joseph Hopper
Journal:  Dig Dis Sci       Date:  2009-09-04       Impact factor: 3.199

6.  Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis.

Authors:  Prashant Kedia; Russell D Cohen
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

7.  Molecular mechanisms by which casein glycomacropeptide maintains internal homeostasis in mice with experimental ulcerative colitis.

Authors:  Yongbo Cui; Chenchen Zhu; Zhu Ming; Jiangming Cao; Yali Yan; Pei Zhao; Guangchang Pang; Zixin Deng; Yi Yao; Qingsen Chen
Journal:  PLoS One       Date:  2017-07-10       Impact factor: 3.240

8.  Alcohol decreases intestinal ratio of Lactobacillus to Enterobacteriaceae and induces hepatic immune tolerance in a murine model of DSS-colitis.

Authors:  Paulius V Kuprys; Abigail R Cannon; Jennifer Shieh; Noama Iftekhar; Sun K Park; Joshua M Eberhardt; Xianzhong Ding; Mashkoor A Choudhry
Journal:  Gut Microbes       Date:  2020-11-09

Review 9.  Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis.

Authors:  Stephan Karl Böhm; Wolfgang Kruis
Journal:  Clin Exp Gastroenterol       Date:  2014-09-23

Review 10.  Can molecular stratification improve the treatment of inflammatory bowel disease?

Authors:  Claire Wang; Hannah M Baer; Daniel R Gaya; Robert J B Nibbs; Simon Milling
Journal:  Pharmacol Res       Date:  2019-09-03       Impact factor: 7.658
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.